Current studentsExisting staffContact us
 

Nuances to precision dosing strategies of targeted cancer medicines

Simple item page
dc.contributor.authorHopkins, A.M.
dc.contributor.authorMenz, B.D.
dc.contributor.authorWiese, M.D.
dc.contributor.authorKichenadasse, G.
dc.contributor.authorGurney, H.
dc.contributor.authorMcKinnon, R.A.
dc.contributor.authorRowland, A.
dc.contributor.authorSorich, M.J.
dc.date.issued2020
dc.description.abstractSelecting the dose of a targeted cancer medicine that is most appropriate for a specific individual is a rational approach to maximize therapeutic outcomes and minimize toxicity. There are many different options for optimizing the dose of targeted cancer medicines and the purpose of this review is to provide a comprehensive comparison of the main options explored in prospective studies. Precision initial dose selection of targeted cancer therapies has been minimally explored to date; however, concentration, toxicity, and therapeutic outcome markers are used to guide on-therapy dose adaption of targeted cancer therapies across several medicines and cancers. While a specific concentration, toxicity, or therapeutic outcome marker commonly dominates an investigated precision on-therapy dose adaption strategy, greater attention to simultaneously account for exposure, toxicity, therapeutic outcomes, disease status, time since treatment initiation and patient preferences are required for optimal patient outcomes. To enable successful implementation of precision dosing strategies for targeted cancer medicines into clinical practice, future prospective studies aiming to develop strategies should consider these elements in their design.
dc.identifier.citationPharmacology Research & Perspectives, 2020; 8(4, article no. e00625):1-9
dc.identifier.doi10.1002/prp2.625
dc.identifier.issn2052-1707
dc.identifier.issn2052-1707
dc.identifier.urihttps://hdl.handle.net/11541.2/143724
dc.language.isoen
dc.publisherJohn Wiley & Sons
dc.relation.fundingCancer Council South Australia
dc.relation.fundingNational Breast Cancer Foundation PF‐17‐007
dc.rightsCopyright 2020 The author(s). This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (https://creativecommons.org/licenses/by-nc/4.0/)
dc.source.urihttps://doi.org/10.1002/prp2.625
dc.subjectinitial dose selection
dc.subjecton-therapy dose adaptation
dc.subjectprecision dosing
dc.subjectprospective studies
dc.titleNuances to precision dosing strategies of targeted cancer medicines
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12202091650001831 13202082440001831 prp2.625.pdf
ror.mmsid9916426280401831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
9916426280401831_12202091650001831_prp2.625.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections